Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting1
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

not_yet_recruiting133%
completed133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

NCT06397274
withdrawnphase_1

Safety Study of Stemchymal® in Acute Liver Failure

NCT03629015
completedphase_2

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

NCT02540655

Clinical Trials (3)

Showing 3 of 3 trials
NCT06397274Phase 2

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

Not Yet Recruiting
NCT03629015Phase 1

Safety Study of Stemchymal® in Acute Liver Failure

Withdrawn
NCT02540655Phase 2

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3